This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Heart attacks Remove Heart Dysfunction Remove Outcomes
article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. Researchers tracked outcomes for a median of just under 18 months. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries.

Heart Attack 98
Heart Attack Heart attacks Heart Failure Outpatient 98
article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart Attack 81
Heart Attack Heart attacks Heart Failure Outcomes 81
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join thousands of Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024